Showing posts with label Pharma. Show all posts
Showing posts with label Pharma. Show all posts

Saturday, December 27, 2014

MedlinePlus: Trusted Health Information for You

Not everything on internet is true, that's true! Especially regarding human health: there's so much info written by people with no medical or biological education and experience. That leads to misinformation and often wrong decisions.  We like to ask other people on social media, forums and etc., and  sometimes  untruth would become truth, just because someone didn't check the original source of information.

This is a real problem and has very simple solution: 

"for medical questions ask your doctor, not "doctor" google!

Well, we all heard that many many times,  but sometimes we just want to find something extra, some more info that our doctor didn't have time to tell us about. In that case, check here: MedlinePlus: Trusted Health Information for You . 
It is supported by the National Institutes of Health. The largest bio-medical institute in the world so that's reliable enough.
Good source for reliable medical info are the government health care websites as well, because are written by doctors and scientists. 


Friday, February 28, 2014

Madame Curie Bioscience Database for free

Free bioscience articles for doctors, students and anyone interested in the field.

Friday, May 10, 2013

Cranberries - the fruits that might fight cancer

Fruits are good for to maintain a good health - that's a fact that everybody knows. We have all heard about many, more or less exotic fruits that have potential anticancer abilities, but who knew that a common and well known fruit as the cranberry would be "the miracle" anticancer fruit?! The studies are promising, so  just add cranberries to your diet and be healthier. They are quite tasty as well.
If you love to eat lemons, apples or red grapes, that's good because they also have shown a good anticancer potential.


http://www.cancer.med.umich.edu/support/cranberries.shtml

Saturday, December 29, 2012

Harvard Health Letter: A conversation with Dr. Jerry Avorn about drugs and the drug industry



A conversation with Dr. Jerry Avorn about drugs and the drug industry

"Americans spend more than $300 billion a year on prescription drugs. How we use these drugs, and how effective they are, have become important subjects for public health researchers. A leader in this area is Dr. Jerry Avorn, chief of the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women’s Hospital in Boston and professor of medicine at Harvard Medical School. Avorn is the author of numerous articles and the book Powerful Medicines.
For an article in the Harvard Health Letter, editor Peter Wehrwein spoke with Avorn about generic drugs, the pharmaceutical industry, the high cost of cancer drugs, and more."

Thursday, September 20, 2012

Nature Reviews Drug Discovery: Different approaches that are being investigated to harness the immune system to treat cancer.

"The video takes an audio-visual journey through the different approaches that are being investigated to harness the immune system to treat cancer.
For more, check out the Nature Reviews Drug Discovery poster: http://www.nature.com/nrd/posters/cancerimmuno/index.html "



Sunday, July 29, 2012

DILI-sim Initiative - computational model for fast and precise prediction of drug-induced liver damage


"The Hamner Institutes for Health Sciences (The Hamner) has announced the formation of the DILI-sim Initiative, a pre-competitive partnership between The Hamner and a diverse set of stakeholders to develop a computational model that will predict whether new drug candidates will cause drug-induced liver injury (DILI) in patients. The goals of the Initiative are to improve patient safety, reduce the need for animal testing, and reduce the costs and time necessary to develop new drugs. It is the intent of the DILI-sim Initiative to make the model, in the form of DILIsym
TM software, broadly available so that it may be used by the pharmaceutical industry, the U.S. Food and Drug Administration (FDA), and other entities in academia, government and industry."
http://www.thehamner.org/news-events/entry/the-hamner-institutes-for-health-sciences-announces-formation-of-dili-sim-i
http://www.thehamner.org/institutes-centers/institute-for-drug-safety-sciences/dili-sim-initiative/
http://www.thehamner.org/content/Hamner_DILI-sim_Flyer.pdf

Sunday, June 24, 2012

DrugBank database - the place where you can learn more about the drugs (medicines, medications)

The DrugBank database: http://www.drugbank.ca/  is a useful source of detailed  information about the drugs approved by FDA and some experimental drugs. It is not only for scientists, health care and pharma professionals, but as well for everyone that wants to know more about the  drugs (medicines, medications). Very user-friendly: just write the name of the drug as you know it and will get a detailed information about it.



*The photo collage was made by me using clip arts from Microsoft Office PowerPoint 2003.

Thursday, June 14, 2012

Tab4Lab - tablet computers make the lab work breeze

Tablet comutrs are easy to use and compact, so it is not surprise that could find many uses in the lab. Tab4Lab is a new product that will help a lot with the implementation of the microscope work with no need of extra space.


Wednesday, June 6, 2012

Technologyreview.com: Using Parents' Blood to Decode the Genome of a Fetus



"For the first time, scientists have deciphered the genome of a fetus using only DNA from the unborn child's parents. The advance represents a significant step forward in the effort to create noninvasive genetic tests that could assess a wide array of genetic diseases.
A small percentage of the DNA in a pregnant woman's blood comes from her fetus, a fact that scientists have begun exploiting to create prenatal genetic tests that don't require invasive sampling of fluid from the uterus. So far, tests have been limited to specific measures such as the genetic aberration that leads to Down syndrome; but the ability to sequence the entire fetal genome suggests that parents could someday get a much broader picture of their baby's disease risk before birth."
COURTNEY HUMPHRIES Technologyreview.com
http://www.technologyreview.com/news/428101/using-parents-blood-to-decode-the-genome-of-a/?ref=rss

*The photo is  From Microsoft Clip Art.



Thursday, May 24, 2012

The world’s first nucleic acid-based test for viral infections - hopefully soon at any hospital


"“DNA or RNA-based tests have repeatedly shown greater sensitivity and specificity over commonly used rapid immunochemistry-based testing methods, but have not been simplified to the extent that they can be moved to a POC setting,” explains David Mead, Ph.D., Lucigen founder and CEO. “We're developing the world’s first nucleic acid-based test for viral infections that is cost effective and can be safely and easily used directly at the physician’s office.” Lucigen believes the platform could form the basis of a multiplex system for testing a range of serious infectious agents at low resource and battlefield settings, and potentially in the future be developed as an OTC device."

Source:

Monday, April 9, 2012

ACToR - online archive all publicly available chemical toxicity data

"ACToR is EPA's online warehouse of all publicly available chemical toxicity data and can be used to find all publicly available data about potential chemical risks to human health and the environment. ACToR aggregates data from over 1000 public sources on over 500,000 environmental chemicals searchable by chemical name, other identifiers and by chemical structure. 

The data warehouse:

  • Allows users to search and query data from other EPA chemical toxicity databases including:
  • ToxRefDB (30 years and $2 billion worth of animal toxicity studies).
  • ToxCastDB (data from screening 1,000 chemicals in over 500 high-throughput assays).
  • ExpoCastDB (consolidate and link human exposure and exposure factor data for chemical prioritization).
  • DSSTox (provides high quality chemical structures and annotations).
  • Includes chemical structure, physico-chemical values, in vitro assay data and in vivo toxicology data.
  • Includes, but not limited to, high and medium production volume industrial chemicals, pesticides (active and inert ingredients), and potential ground and drinking water contaminants."

*
http://actor.epa.gov/actor/faces/ACToRHome.jsp;jsessionid=C4AD44FB4880C2565790FC52DE67F1EE

Wednesday, February 1, 2012

The lack of creativity in the Pharma Industry

I recently read an article in IDEA Junkie that express my thoughts about the lack of creativity in the Pharma Industry. Here is the full text.




Humanity is dead  
http://www.ideapharma.com/announcements/humanity-is-dead 
By Pankaj Oza

Humans are imaginative beings; our survival has depended upon it over hundreds of thousands of years. Imagination and innovation have spurred survival instincts to ensure humanity has prospered over generations through adaptation. An ability to sense adverse conditions and to then adapt accordingly has driven successful creation and inhabitation of new communities.
This imagination continues to be seen in all walks of life, however more recently it can be argued that the progress of humanity is coming to a plateau. How further can innovation continue to extend both the quantity and quality of our lives? How much longer can we extend our lives? How much more can we pack into our lives? How ‘productive’ actually are we?  Does the time we spend at work truly deliver ‘productivity’?  
If we compared the time spent on our chosen activities, the time with our friends, the time with our families with the time at work, would we recognise ourselves? The environments within which we find ourselves clearly impact our attitude and approach and our subsequent ability utilize our inherent creativity. What fosters the appropriate environment to drive our creativity inherent in all of us?
The need for survival clearly focuses our minds and fosters enhanced ingenuity and creativity. Electric cars, wind farms, solar panels, nuclear power… have all derived from a necessity for alternatives in a resource constrained environment.
But why does it take an impending disaster for us to turn on our creativity? Why do certain environments foster creativity? Why does creating a meal incorporate so much more creativity that answering our emails at work?
Pharma is in a bad place and the reason Pharma is currently struggling is because the lack of creativity, absence of thought that goes into everyday tasks. The way in which we formulate a drug matters. The means by which we design a clinical study matters. The means by which we choose specific end points matters. The population we define in which to study a drug matters. The options we develop to outline the possibilities for a molecule matters.
If Pharma could only spend a little bit of time utilising individuals’ natural creativity and taking just a little more time and creative thought to design molecules, Pharma would be in a different place. Until that time, the impending doom of blockbusters losing exclusivity will continue to define our industry. 



Thursday, December 8, 2011

"What if we could simply "print" new organs for use in clinical trials?"

"What if we could simply "print" new organs for use in clinical trials? Gabor Forgacs from Organovo tells us about a radical new approach to tissue engineering."






Wednesday, October 26, 2011

A Small Revolution | The Scientist

A Small Revolution | The Scientist

October 2011 » Special Issue Feature

A Small Revolution

In fewer than 15 years, nanomedicine has gone from fantasy to reality.

By Erica Westly | October 1, 2011

"Many trace the origins of nanomedicine to a talk Richard Feynman gave at Caltech in 1959—There’s Plenty of Room at the Bottom. During the lecture, Feynman proposed the idea of chemical manipulation at the atomic level and suggested that patients might one day “swallow the surgeon” in the form of tiny machines. Some 50 years later, researchers are still working to realize these dreams, but Feynman would no doubt be impressed by the list of nanomedicine applications being developed today. Nanomaterials have made their way into drug-delivery systems and diagnostics, and are quickly becoming essential basic research tools."

Saturday, October 8, 2011

FDA Takes On Personalized Medicine

Personalized medicine does not fit easily into established government procedures for approving drugs. After all, clinical trials are designed to test a drug on a large and diverse group of patients, and the whole point of personalized therapeutics is to target the specific genetic populations that will benefit most. The U.S. Food and Drug Administration is now trying to figure out how to judge the usefulness of a drug designed for particular genetic groups while also considering its safety for others who may receive it for off-label purposes.
 COURTNEY HUMPHRIES


Technology Review

Tuesday, August 30, 2011

So how long humans can actually live?

Many of us are wondering how long we can live?! Is there any way to be young longer? 
In the recent 50-60 years the life span has extended, but is often surrounded by many age-related diseases. Could the sequencing of the human genome and the recent discoveries in the genetics help us live a longer, and healthier life?
I have read an interesting interview with two of the leading scientists in the field of human ageing, where they answer these questions:
Lenny GUARENTE, PH.D.is a professor of biology at M.I.T. and author of "Ageless Quest: One Scientist's Search for Genes That Prolong Youth". 
Robert N. BUTLER, M.D. is a founding director of the National Institute on Aging, a founder of the Alzheimer's Disease Association and winner of a Pulitzer Prize in 1976 for "Why Survive? Being Old in America." He heads the International Longevity Center.; SARA DAVIDSON: Author, most recently, of "Leap! What Will We Do With the Rest of Our Lives?"
Here are some of the most interesting parts of the interview with the journalist Sara Davidson, published in the New York Times. 


Dr. GUARENTE, scientists like J. Craig Venter, one of the first to map the human genome, feel that increasing life span should not be the goal of science. Why are you attempting to prolong life?
LENNY GUARENTE: The research that I’m involved in is not about extending life after people are infirm. I don’t think of life span as the gold standard. The gold standard is health span. All the indicators from the laboratory are that the genes we’re studying and the kinds of drugs we would be developing would extend health span. If you can extend health span, and you also happen to extend life span, so be it. That’s a side benefit.


Have you identified genes that can extend health and life span?
GUARENTE: The genes we study counteract aging. First we studied yeast cells, and it took us eight years to identify a gene called SIR2, which protects the cells from damage during the aging process. Then we did a similar experiment in a more complex critter, the roundworm, and what was remarkable is, we identified the same gene. That told us that this type of gene is performing an antiaging function broadly in nature.


Do humans have this gene?
GUARENTE: There’s one gene in our genome, SIRT1, that would be a dead ringer for this one — the technical term is ortholog — but we also have six other genes that have a related sequence to this. They’re called sirtuins, and they’re all going to play a role, but I think the dead ringer is undoubtedly the most important based on experiments that have been done.

You assert a fairly radical concept: that these longevity genes have the power to keep the body supercharged and maintaining its natural repair activities regardless of age. Does that mean we could live, what, another 20, 30 years? Fifty?
GUARENTE: We think the sirtuin genes are there to recognize lack of food or other stressful situations and to spring into action to create a physiology that will promote longevity. The evolutionary value is that in times of stress — food scarcity, for example — this gene would slow down the aging process and keep you alive longer, so that when times are better, you could reproduce.


But how long would the gene work? Maybe it only operates temporarily?

GUARENTE: We can gauge this by asking what happens in rodents on a calorie-restricted diet, which mimics food scarcity and activates the SIR2 gene. Do they live forever? No. They live up to 50 percent longer. So in a perfect world, one would hope that we could live 50 percent longer than the current expected life span.

In our lifetimes, could this happen?
GUARENTE: I think one can expect perhaps another decade of robust health.

ROBERT BUTLER: A lot of it comes down to our willingness in this country to make an investment in the biology of aging. Historically, we’ve devoted our energies and money to studying one disease at a time. At the same time, we have neglected targeting the underlying risk factor of aging.

Are you saying that aging itself leads to disease?
BUTLER: Why does 50 percent of all cancer occur after 65? Why does 80 percent occur after age 50? As we age, there are changes at the cellular molecular level that predispose us to disease and disability. But so far, no government, no foundation, no corporation anywhere in the world has fully embraced the importance of longevity science. If we could target aging, that would have an impact on diseases.

What do you mean “target” aging?
GUARENTE: Slow down aging in the same way that calorie restriction slows down aging. Bob makes an important point about diseases and aging. I believe that the two are intertwined and experimentally this has been demonstrated by using modern strains of mice that have been genetically altered to get specific diseases — for example, neurodegenerative diseases or cancer, or cardiovascular disease or diabetes — and to see whether calorie restriction will either postpone or prevent these diseases. The general finding is that calorie restriction forestalls many of these diseases. The hypothesis is that if one could activate the sirtuin genes — not by a calorie-restricted diet but pharmacologically — then this would have an impact on the diseases of aging.

How close are we to such a drug being available?
GUARENTE: Ten, maybe 15 years. I think the drugs that aim at sirtuins, for example, will be tested initially for a particular disease, say, diabetes. And it will turn out that the drugs have broader benefits than one initially imagined.

There are substances on the market now that claim to prolong life — and people are spending billions on them. What’s the distinction between these products and the drugs that you’re hoping to develop?

GUARENTE: Well, that’s really simple. Any product on the market that claims to extend life — don’t believe it.

BUTLER: That’s true. We don’t yet have the means to delay, stop or reverse aging. And in fact, we don’t even have the means to evaluate or measure whether a substance prolongs life. We have yet to create biomarkers that would measure, short of death, actual changes in the body that reflect aging.

Let’s talk for a minute philosophically. What kind of society will we have if everybody is living to 100, and the whole culture skews older?
BUTLER: You could have asked that same question in 1900, when the average life expectancy was 47. Someone might have said, what are we going to do when we have all these 55- and 60-year-olds around? Society adjusts. People think we can’t afford older people because of Social Security and Medicare. But there’s a growing body of knowledge by hard-nosed economists of all ideological persuasions — University of Chicago, Yale, Harvard, the RAND Corporation — that as societies become more long-living and healthier, that actually creates greater wealth. Bloom and Canning up at Harvard have shown that if you identify nations that have a five-year difference in life expectancy, the one that has a greater life expectancy also has greater wealth. Older people create silver markets, so that one person’s cost, like health costs, is another person’s income, asset or job.

What about the institution of marriage? If you’re going to live to 100 and get married at 22 or 25. ...
BUTLER: Oh, you are evil.

Are you still going to vow “till death do us part”?
BUTLER: There’s a demographer, Peter Uhlenberg, who said that divorce is a substitute for death, because in the old days there was enough death, unfortunately, particularly of women in childbirth, that the men would remarry. Someone even calculated that marriage now lasts about as long as it did then, but it was ended then by death rather than by divorce. So maybe you’re onto something.

Are you concerned that extending life span could double the number of people alive and overwhelm the planet’s resources?
GUARENTE: I don’t believe that mitigating the diseases of aging will lead to overpopulation, because in most of the developed world birthrates are low or declining.
BUTLER: They’re falling in the developing world as well. There’s a distinction between advancing life expectancy and breaking the genetic barrier. Every species has a predetermined genetic life span. Certain fish live about a year. Some turtles live 200 years. Humans have about 110, 120 years at the outside of their genetic life span. We’re talking about increasing healthy years within that life span.